肾性贫血

静脉铁剂治疗血液透析肾性贫血患者的疗效观察

Observing the Effect of Intravenous Iron on Renal Anemia Patients with Hemodialysis

表达EPO基因裸质粒治疗肾性贫血的实验研究

Experimental Study of the Effect of Naked Plasmid Expressing EPO on Renal Anemia

方法：将88例肾性贫血病人随机分为治疗组（A组）58例，和对照组（B）组30例。

Methods : The 88 patients with ARF randomly devided into two groupe , the curative groupe ( A groupe ) 58 patients ,, and the control groupe ( B groupe ) 30 patients .

在纠正肾性贫血上，治疗组较治疗前血红蛋白升高（P0.05）；治疗组优于对照组（P0.05）。

In correcting renal anemia , the treatment group compared with pre-treatment increased hemoglobin ( P0.05 ); the treatment group than the control group ( P0.05 ) .

方法用腺嘌呤灌胃建立大鼠肾性贫血模型，治疗组加用GP。

Methods We established a rat model of chronic renal anemia with adenine , which was then treated with gypenoside .

慢病毒介导EPO基因治疗肾性贫血大鼠的实验研究

Experimental research on EPO gene therapy of anemia caused by chronic renal failure by means of lentivirus mediation in rat

目的研究绞股蓝总皂甙（gypenoside，GP）对肾性贫血大鼠血浆促红细胞生成素（erythropoietin，EPO）含量的影响。

Objective To investigate the effect of gypenoside ( GP ) on erythropoietin in rats with chronic renal anemia .

目的研究电脉冲介导的质粒红细胞生成素（EPO）基因肌肉转移效率以及对肾性贫血的治疗作用。

Objective To investigate the effects of erythropoietin ( EPO ) gene transfer into skeleton muscle mediated by electroporation on renal anemia .

肾性贫血主要是由于肾脏产生红细胞生成素（EPO）不足而引起，这类贫血主要靠补充外源性EPO进行治疗。

Renal anemia is mostly caused by insufficient EPO produced by kidney , which mainly required to be treated with external EPO .

方法：54例维持血液透析的肾性贫血患者随机分为三组：A组18例，透析后静脉注射左旋卡尼汀1g；

Methods : Fifty-four maintenance hemodialysis patients with anemia were randomly divided into 3 even groups .

结论：MHD患者健康相关生存质量差，受多种因素影响，其中肾性贫血是影响透析患者生存质量的重要因素。

Conclusion MHD patients have lowered HRQL and many related risk factors , of which renal anemia plays an important role in decrease HRQL .

结论MHD患者动-静脉内瘘手术的次数及肾性贫血、体内慢性炎症状态与抑郁症的发生有关。

Conclusion The development of depression in MHD patients was correlated with the times of arterio-venous fistula operation , anemia and chronic inflammatory status .

目的比较维持性血液透析患者口服和静脉补铁治疗肾性贫血的疗效，以及对促红细胞生成素（EPO）作用的影响。

Objective To compare the efficiency of intravenous and oral iron and influence of erythropoietin ( EPO ) in the patients undergoing maintenance hemodialysis .

结论：肾性贫血具有FEP增高及铁负荷增加等特点。

Conclusion : The anaemia due to chronic renal dysfunction is characterized of high level of FEP and overload iron .

为了比较国产和进口rhEPO对肾性贫血的疗效和安全性，我们进行了多中心临床对照试验。

In order to compare the efficacy of domestic and imported rhEPO , we conducted multicentered controlled clinical trial .

本文就炎症与CRF患者动脉粥样硬化、营养不良、肾性贫血、促红细胞生成素抵抗等并发症的关系及其治疗进行综述。

The article reviews the relationship between inflammation in patients with CRF and atherosclerosis , malnutrition , renal anemia , resistance of erythropoietin and treatment to inflammation .

本文提出肾性贫血EPOR异常学说。

In this article , an assumption of EPOR abnormality in renal anemia is put forward .

结论：金水宝胶囊具有调节和保护CRF患者红细胞免疫功能的作用，并能改善肾性贫血及改善肾功能。

Conclusions : JSBC possesses regulating and protecting actions on immune functions of RBC in patients with CRF and is able to improve renal anemia and renal functions .

目的分析维持性血液透析（MHD）患者肾性贫血与健康相关生存质量（HRQL）的关系。

Objective To survey the relationships between anemia and health-related quality of life ( HRQL ) among maintenance hemodialysis ( MHD ) patients .

分析MHD患者肾性贫血程度、营养状况和炎症状态等与HRQL的关系。

Nephrogenic anemia , nutritional status and inflammatory condi - tions among this population were analyzed and correlation of nephrogenic anemia with HRQL was evaluated .

目的：观察健脾补肾泄浊法配合促红细胞生成素（EPO）治疗肾性贫血的临床疗效。

Objective : To observe the curative effect of the therapy of strengthening the spleen , tonifying the kidney and eliminating turbid urine combined with erythropoietin ( EPO ) in treating renal anemia .

结论：肾性贫血患者Epo水平与Hb浓度无相关性，其贫血程度虽然主要取决于Epo水平，但它不是唯一因素。

Conclusion : There are no correlativity between the Epo and Hb concentration in renal anemia patients . Although the Epo level is an important factor of anemia severity , yet it is not a sole factor .

目的：证实国产人基因重组红细胞生成素（rHuEPO）纠正终末期肾病（ESRD）患者肾性贫血的疗效。

Objective : To prove the effect of recombinant human erythropoietin ( rHuEPO ) made in China to treat renal anemia of end stage renal disease ( ESRD ) .

目的：比较静脉注射右旋糖酐铁和口服硫酸亚铁分别与重组人红细胞生成素（rhEPO）联合应用，治疗伴有缺铁的血液透析患者肾性贫血的有效性和安全性。

Objective : To determine and compare the effectiveness and safety of intravenous iron supplementation with oral ferrous sulfate in hemodialysis patients treated with recombinant human erythropoietin ( rhEPO ) .

目的：观察丙酸睾丸酮与小剂量的重组人促红细胞生成素（rHuEPO）治疗慢性肾性贫血的临床疗效及其不良反应。

Objective : To evaluate the clinical and side effects of testosterone and small dosage recombinant human erythropoietin ( rHuEPO ) to treat anemic patients with chronic renal failure .

研究背景：肾性贫血是慢性肾功能衰竭（CRF）患者常见的临床表现，主要由于慢性肾功能衰竭患者肾小管功能受损，导致红细胞生成素生成减少是引起肾性贫血的直接原因。

Research background Renal anemia caused mainly by renal tubular dysfunction , is a common clinical manifestation in patients with chronic renal failure . It causes reduction of erythropoietin , which is the direct reason for renal anemia .

结论静脉补铁治疗维持性血液透析的慢性肾衰患者铁缺乏、改善肾性贫血有效，疗效优于口服补铁，配合EPO治疗效果明显，从而减少输血。

Conclusion Is the maintenance treatment of intravenous iron Section chronic kidney hemodialysis patients iron deficiency , anaemia improve kidney effective , superior efficacy of oral supplementation with EPO treatment results clearly , thereby reducing the blood transfusion .

目的：对维持性血液透析（MHD）患者肾性贫血和健康相关生存质量进行研究，为其预后判断、药物疗效的分析及药品经济学评估提供依据。

Objective To investigate renal anemia and health-related quality of life ( HRQL ) among maintenance hemodialysis ( MHD ) patients and to provide evidences for the prognostic judgement , pharmacodynamic analysis and physic economic evaluation on this population .

方法经动物皮下注射后比较PEG-rhEPO与普通rhEPO在网织红细胞百分数（RET%）、用药频度、肾性贫血纠正以及对病模动物的保护作用。

PEG-rhEPO into animals and compare the percentage of reticulocyte ( RET % ) . frequency of administration . rectification of renal anemia as well as the protection against death with those injected with rhEPO .

目的了解慢性系统疾病性贫血中肝性贫血、肾性贫血、糖尿病性贫血患者的红细胞分布宽度（RDW）的差异，探讨RDW的临床实验室辅助诊断价值。

Objective To explore the differences of red cell distribution width ( RDW ) among patients with anemia of chronic systemic disease involving hepatic anemia , renal anemia and diabetic anemia , and to determine the diagnosis value of RDW .